Urology
Volume 61, Issue 1 , Pages 30-36 , January 2003

Failure after radical prostatectomy

  • Endre Z Neulander

      Affiliations

    • Department of Urology, Soroka Medical Center, Ben Gurion University, Beer Sheva, Israel
    • ,
  • Mark S Soloway

      Affiliations

    • Department of Urology, University of Miami School of Medicine, Miami, Florida, USA
    • Corresponding Author InformationReprint requests: Mark S. Soloway, M.D., Department of Urology, University of Miami School of Medicine, P.O. Box 016960 (M814), Miami, FL 33101, USA

Received 1 June 2001 ,Accepted 17 June 2002.

References 

  1. Ornstein DK, Colberg JW, Virgo KS, et al.  Evaluation and management of men whose radical prostatectomies failed (results of an international survey). Urology. 1998;52:1047–1054
  2. Pound CR, Partin AW, Epstein JI, et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy (patterns of recurrence and cancer control). Urol Clin North Am. 1997;24:395–406
  3. Pound CR, Partin AW, Eisenberger MA, et al.  Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  4. Obek C, Sadek S, Lai S, et al.  Positive surgical margins with radical retropubic prostatectomy (anatomic site-specific pathologic analysis and impact on prognosis). Urology. 1999;54:682–688
  5. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer (intermediate-term results). J Urol. 1998;160:2428–2434
  6. Kupelian PA, Katcher J, Levin HS, et al.  Stage T1-2 prostate cancer (a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy). Int J Radiat Oncol Biol Phys. 1997;37:1043–1052
  7. Jhaveri FM, Zippe CD, Klein EA, et al.  Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer (10-year results). Urology. 1999;54:884–890
  8. Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 14(2 suppl 2): 12–21, 1996
  9. Partin AW, Pound CR, Clemens JQ, et al.  Serum PSA after anatomic radical prostatectomy (the Johns Hopkins experience after 10 years). Urol Clin North Am. 1993;20:713–725
  10. Partin AW, Kattan MW, Subong EN, et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer (a multi-institutional update). [published erratum appears in JAMA 278: 118, 1997] JAMA. 1997;277:1445–1451
  11. Epstein JI, Partin AW, Sauvageot J, et al.  Prediction of progression following radical prostatectomy (a multivariate analysis of 721 men with long-term follow-up). Am J Surg Pathol. 1996;20:286–292
  12. Stein A, deKernion JB, Dorey F, et al.  Adjuvant radiotherapy in patients post-radical prostatectomy with tumor extending through capsule or positive seminal vesicles. Urology. 1992;39:59–62
  13. Wheeler TM, Dillioglugil O, Kattan MW, et al.  Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998;29:856–862
  14. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol. 1998;160:299–315
  15. Grossfeld GD, Chang JJ, Broering JM, et al.  Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment (data from the CaPSURE database). J Urol. 2000;163:1171–1177 (quiz 1295)
  16. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–1507
  17. Obek C, Neulander E, Sadek S, et al.  Is there a role for digital rectal examination in the followup of patients after radical prostatectomy?. J Urol. 1999;162((3 Pt 1):):762–764
  18. Pound CR, Christens-Barry OW, Gurganus RT, et al.  Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol. 1999;162:1337–1340
  19. Lightner DJ, Lange PH, Reddy PK, et al.  Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 1990;144:921–926
  20. Patel A, Dorey F, Franklin J, et al.  Recurrence patterns after radical retropubic prostatectomy (clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen). J Urol. 1997;158:1441–1445
  21. Jhaveri FM, Klein EA. How to explore the patient with a rising PSA after radical prostatectomy (defining local versus systemic failure). Semin Urol Oncol. 1999;17:130–134
  22. Fowler JE, Brooks J, Pandey P, et al.  Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy. J Urol. 1995;153(3 Pt 2):1011–1014
  23. Saleem MD, Sanders H, Abu El Naser M, et al.  Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology. 1998;51:283–286
  24. Shekarriz B, Upadhyay J, Wood DP, et al.  Vesicourethral anastomosis biopsy after radical prostatectomy (predictive value of prostate-specific antigen and pathologic stage). Urology. 1999;54:1044–1048
  25. Koppie TM, Grossfeld GD, Nudell DM, et al.  Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?. J Urol. 2001;166:111–115
  26. Partin AW, Pearson JD, Landis PK, et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994;43:649–659
  27. Seltzer MA, Barbaric Z, Belldegrun A, et al.  Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 1999;162:1322–1328
  28. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000;163:1632–1642
  29. Kahn D, Williams RD, Haseman MK, et al.  Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol. 1998;16:284–289
  30. Leibovich BC, Engen DE, Patterson DE, et al.  Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol. 2000;163:1178–1182
  31. Morris MM, Dallow KC, Zietman AL, et al.  Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 1997;38:731–736
  32. Vicini FA, Ziaja EL, Kestin LL, et al.  Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology. 1999;54:111–117
  33. Petrovich Z, Lieskovsky G, Langholz B, et al.  Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate. Am J Clin Oncol. 1999;22:323–331
  34. Valicenti RK, Gomella LG, Ismail M, et al.  Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer (the importance of radiation dose). Urology. 1998;52:1034–1040
  35. Valicenti RK, Gomella LG, Ismail M, et al.  Pathologic seminal vesicle invasion after radical prostatectomy for patients with prostate carcinoma (effect of early adjuvant radiation therapy on biochemical control). Cancer. 1998;82:1909–1914
  36. Grossfeld GD, Tigrani VS, Nudell D, et al.  Management of a positive surgical margin after radical prostatectomy (decision analysis). J Urol. 2000;164:93–100
  37. Valicenti RK, Gomella LG. Durable efficacy of adjuvant radiation therapy for prostate cancer (will the benefit last?). Semin Urol Oncol. 2000;18:115–120
  38. Rogers R, Grossfeld GD, Roach M, et al.  Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J Urol. 1998;160:1748–1753
  39. Pisansky TM, Kozelsky TF, Myers RP, et al.  Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000;163:845–850
  40. Tiguert R, Forman JD, Hussain M, et al.  Radiation therapy for a rising PSA level after radical prostatectomy. Semin Urol Oncol. 1999;17:141–147
  41. Nudell DM, Grossfeld GD, Weinberg VK, et al.  Radiotherapy after radical prostatectomy (treatment outcomes and failure patterns). Urology. 1999;54:1049–1057
  42. Schild SE, Buskirk SJ, Wong WW, et al.  The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol. 1996;156:1725–1729
  43. Garg MK, Tekyi-Mensah S, Bolton S, et al.  Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology. 1998;51:998–1002
  44. Cox JD, Gallagher MJ, Hammond EH, et al.  American Society for Therapeutic Radiology and Oncology Consensus Panel   Consensus statements on radiation therapy of prostate cancer (guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy). J Clin Oncol. 1999;17:1155
  45. Nelson WG, Simons JW. New approaches to adjuvant therapy for patients with adverse histopathologic findings following radical prostatectomy. Urol Clin North Am. 1996;23:685–696
  46. Mayer FJ, Crawford ED. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. Urol Clin North Am. 1994;21:707–715
  47. Messing EM, Manola J, Sarosdy M, et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788
  48. Bruchovsky N, Klotz LH, Sadar M, et al.  Intermittent androgen suppression for prostate cancer (Canadian prospective trial and related observations). Mol Urol. 2000;4:191–200
  49. Goldenberg SL, Bruchovsky N, Gleave ME, et al.  Intermittent androgen suppression in the treatment of prostate cancer (a preliminary report). Urology. 1995;45:839–845
  50. Zerbib M, Conquy S. Intermittent hormonal treatment in prostatic cancer. Prog Urol. 1997;7:1026–1027
  51. Bouchot O, Lenormand L, Karam G, et al.  Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol. 2000;38:543–549
  52. Bhayani SB, Andriole GL. Hormonal manipulation for rising PSA after radical prostatectomy. Semin Urol Oncol. 1999;17:148–153
  53. Iversen P, Tyrrell CJ, Kaisary AV, et al.  Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer (6.3 years of followup). J Urol. 2000;164:1579–1582
  54. Andriole G, Lieber M, Smith J, et al.  Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 1995;45:491–497
  55. Brufsky A, Fontaine-Rothe P, Berlane K, et al.  Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology. 1997;49:913–920

PII: S0090-4295(02)01918-0

Urology
Volume 61, Issue 1 , Pages 30-36 , January 2003

Article Tools